Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles from Albert Einstein Medical Center
Based on 2 articles published since 2010

These are the 2 published articles about Melanoma that originated from Albert Einstein Medical Center during 2010-2020.
+ Citations + Abstracts
1 Article Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. 2016

Gonzalez-Cao, Maria / Boada, Aram / Teixidó, Cristina / Fernandez-Figueras, María Teresa / Mayo, Clara / Tresserra, Francesc / Bustamante, Jean / Viteri, Santiago / Puertas, Enrique / Santarpia, Mariacarmela / Riso, Aldo / Barron, Feliciano / Karachaliou, Niki / Rosell, Rafael. ·Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain. · Dermatology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. · Pangaea Biotech, Laboratory of Oncology, Barcelona, Spain. · Pathology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. · Pathology Department, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain. · Albert Einstein Medical Center, Philadelphia, PA, USA. · Radiotherapy Department, Hospital Quirónsalud, Barcelona, Spain. · Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy. · Medical Oncology Unit, Insituto Nacional de Cancerología, México. · Catalan Institute of Oncology, Cancer Biology & Precision Medicine Programme, Germans Trias i Pujol Hospital and Health Sciences Institute, Badalona, Spain. ·Oncotarget · Pubmed #27447748.

ABSTRACT: Approximately 50% of metastatic melanoma patients harbor BRAF mutations. Several treatment options including the combination of BRAF and MEK inhibitors (BRAF/MEKi) and immunotherapy (mainly anti CTLA-4 and anti PD-1 antibodies), have been shown to improve survival in these patients. Although preclinical data support the synergistic effect of both modalities in combination, data confirming the activity and tolerability of these combinations are not yet available in the clinical setting. Herein, we report the case of a melanoma patient treated with sequential BRAF/MEKi (dabrafenib plus trametinib) followed by the anti CTLA-4 antibody ipilimumab who achieved a pathological complete response. Unfortunately, the patient died due to fatal gastrointestinal (GI) toxicity. Analysis of the BRAFV600E mutation in circulating tumoral DNA (ctDNA) from peripheral blood samples and serial tumor tissue biopsies throughout treatment demonstrated a good correlation with clinical evolution.

2 Article Yttrium-90 Microsphere Brachytherapy for Liver Metastases From Uveal Melanoma: Clinical Outcomes and the Predictive Value of Fluorodeoxyglucose Positron Emission Tomography. 2016

Eldredge-Hindy, Harriet / Ohri, Nitin / Anne, Pramila R / Eschelman, David / Gonsalves, Carin / Intenzo, Charles / Bar-Ad, Voichita / Dicker, Adam / Doyle, Laura / Li, Jun / Sato, Takami. ·*Department of Radiation Oncology ‡Department of Radiology, Division of Interventional Radiology §Department of Radiology, Division of Nuclear Medicine ∥Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA †Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY. ·Am J Clin Oncol · Pubmed #24441583.

ABSTRACT: OBJECTIVES: To report outcomes after yttrium-90 microsphere brachytherapy for unresectable liver metastases from uveal melanoma and to evaluate factors predictive for overall survival (OS) and hepatic progression-free survival (PFS). METHODS: A total of 71 patients were consecutively treated with microsphere brachytherapy for unresectable liver metastases from uveal melanoma between 2007 and 2012. Clinical, radiographic, and positron emission tomography-derived, functional tumor parameters were evaluated by log-rank test in univariate analysis and backwards stepwise multivariate Cox proportional hazards regression. OS and hepatic PFS were estimated by Kaplan-Meier analysis. RESULTS: A total of 134 procedures were performed in 71 patients with a median age of 63 years (range, 23 to 91 y). Fifty-eight patients (82%) received microsphere brachytherapy as a salvage therapy. Median hepatic PFS and OS after microsphere brachytherapy were 5.9 months (range, 1.3 to 19.1 mo) and 12.3 months (range, 1.9 to 49.3 mo), respectively. Median OS times after diagnosis of liver metastases was 23.9 months (range, 6.2 to 69.0 mo). In univariate analysis, female sex, pretreatment metabolic tumor volume, and total glycolic activity (TGA) were significantly correlated with hepatic PFS and OS. In multivariate analysis, female sex and TGA retained significance as independent predictors of hepatic PFS and OS. A low pretreatment TGA (<225 g) was associated with a significantly longer median OS than was a TGA≥225 g (17.2 vs. 9.7 mo, P=0.01). CONCLUSIONS: Yttrium-90 microsphere brachytherapy provided favorable survival times in patients with unresectable liver metastases from uveal melanoma. Metabolic tumor volume and TGA are predictive functional tumor parameters, which may aid patient selection and risk stratification.